Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Cheifetz

Showing results (161-170 of 203) with videos related to

Pageof 21
Sort By:
European Journal of Gastroenterology & Hepatology|March 23, 2026
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseTina Deyhim, Alessandra Saraga, Ajay Gade, et al.
Inflammatory Bowel Diseases|July 2, 2026
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumabJoyce Lee, Rachel Porth, Alessandra Saraga, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 9, 2021
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis FactorNiels Vande Casteele, Maria T Abreu, Sarah Flier, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2020
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, William T Clarke, Niels Vande Casteele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2013
Histologic markers of inflammation in patients with ulcerative colitis in clinical remissionLaura Rosenberg, Kavinderjit S Nanda, Talia Zenlea, et al.
Inflammatory Bowel Diseases|March 1, 2013
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remissionLaura Rosenberg, Garrett O Lawlor, Talia Zenlea, et al.
The American Journal of Gastroenterology|March 16, 2016
Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective StudyTalia Zenlea, Eric U Yee, Laura Rosenberg, et al.
Journal of Clinical Medicine|January 28, 2026
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel DiseaseAlessandra Saraga, Tina Deyhim, Ajay Gade, et al.
Digestive Diseases and Sciences|November 18, 2017
Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private PracticeJoseph D Feuerstein, Konstantinos Papamichael, Sara Popejoy, et al.
Gut|April 7, 2007
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alphaAlan C Moss, Pauline Anton, Tor Savidge, et al.
Pageof 21

Showing results (161-170 of 203) with videos related to

Sort By:
Pageof 21
European Journal of Gastroenterology & Hepatology|March 23, 2026
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseTina Deyhim, Alessandra Saraga, Ajay Gade, et al.
Inflammatory Bowel Diseases|July 2, 2026
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumabJoyce Lee, Rachel Porth, Alessandra Saraga, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 9, 2021
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis FactorNiels Vande Casteele, Maria T Abreu, Sarah Flier, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2020
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, William T Clarke, Niels Vande Casteele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2013
Histologic markers of inflammation in patients with ulcerative colitis in clinical remissionLaura Rosenberg, Kavinderjit S Nanda, Talia Zenlea, et al.
Inflammatory Bowel Diseases|March 1, 2013
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remissionLaura Rosenberg, Garrett O Lawlor, Talia Zenlea, et al.
The American Journal of Gastroenterology|March 16, 2016
Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective StudyTalia Zenlea, Eric U Yee, Laura Rosenberg, et al.
Journal of Clinical Medicine|January 28, 2026
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel DiseaseAlessandra Saraga, Tina Deyhim, Ajay Gade, et al.
Digestive Diseases and Sciences|November 18, 2017
Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private PracticeJoseph D Feuerstein, Konstantinos Papamichael, Sara Popejoy, et al.
Gut|April 7, 2007
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alphaAlan C Moss, Pauline Anton, Tor Savidge, et al.
Pageof 21